MBX

MBX Biosciences Inc

54.06

Nov 09 • 3:59 PM ET +2.71 (5.28%)

53.31

Aftermarket • 7:30 PM ET -0.75 (-1.39%)

Healthcare Biotechnology USA Mid NASD

Today, 6:15 PMMBX Biosciences Inc reports fiscal Q3 2026 results with non-GAAP EPS $-1.29 (-105% YoY) and revenue $0, misses EPS but beats revenue estimates

Peers: ASND KLRA VKTX GPCR PTGX ENTX ALT RYTM RZLT SPRB

| Held by: VTI IWM VXF IWO IBB VTWO XPH FESM SCHA DFAS

Scroll to Statements

Index	RUT
Market Cap	2.60B
Enterprise Value	2.19B
Income	-104.29M
Sales	0.00M
Book/sh	8.54
Cash/sh	8.69
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	63
IPO	Sep 13, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.33
P/C	6.22
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.08
Current Ratio	18.08
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.41
EPS next Y	-3.98
EPS next Q	-0.94
EPS this Y	-29.03%
EPS next Y	-29.74%
EPS next 5Y	-22.84%
EPS past 3/5Y	-44.91% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-4.40%
Sales Y/Y TTM	-
EPS Q/Q	-33.99%
Sales Q/Q	-
Earnings	Nov 09 AMC
EPS/Sales Surpr.	-56.02% -

Insider Own	36.67%
Insider Trans	-0.40%
Inst Own	82.43%
Inst Trans	2.37%
ROA	-31.25%
ROE	-33.17%
ROIC	-25.30%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.90%
SMA50	-3.78%
SMA200	17.70%
Trades

Shs Outstand	47.95M
Shs Float	30.50M
Short Float	14.50%
Short Ratio	8.81
Short Interest	4.42M
52W High	72.64 -25.58%
52W Low	21.90 146.85%
Volatility	7.75% 6.71%
ATR (14)	3.61
RSI (14)	50.78
Beta	0.33
Rel Volume	1.32
Avg Volume	502.09K
Volume	662,975

Perf Week	-0.63%
Perf Month	1.54%
Perf Quarter	-18.10%
Perf Half Y	34.88%
Perf YTD	71.40%
Perf Year	111.42%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.09
Target Price	95.70
Prev Close	51.35
Price	54.06
Change %	5.28%

Consensus

Strong Buy

Avg. Price Target

$95.70

Implied Upside

+77.0%

Analysts11incl. previous ratings

Rating Distribution10 Buy · 0 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 21, 2026	Resumed	JJP Morgan	Overweight	$88	+62.8%
Jan 28, 2026	Initiated	BBarclays	Overweight	$66	+22.1%
Dec 04, 2025	Initiated	GGoldman	Sell	$18	-66.7%
Nov 04, 2025	Initiated	TTD Cowen	Buy
Oct 15, 2025	Initiated	TTruist	Buy	$50	-7.5%
Aug 15, 2025	Resumed	JJefferies	Buy	$36	-33.4%
Aug 05, 2025	Initiated	MMizuho	Outperform	$38	-29.7%
Jul 16, 2025	Initiated	OOppenheimer	Outperform	$38	-29.7%
Apr 10, 2025	Initiated	CCitizens JMP	Mkt Outperform	$38	-29.7%
Oct 08, 2024	Initiated	SStifel	Buy	$40	-26.0%
Oct 08, 2024	Initiated	JJP Morgan	Overweight	$30	-44.5%
Oct 08, 2024	Initiated	JJefferies	Buy	$35	-35.3%
Oct 08, 2024	Initiated	GGuggenheim	Buy	$44	-18.6%

Today 04:01PM	MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +5.28%
Oct-13-26 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -5.81%
Sep-09-26 08:00AM	MBX Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-08-26 08:00AM	MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer (GlobeNewswire)
Aug-27-26 08:00AM	MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism (GlobeNewswire)
07:05PM	Loading…
Aug-14-26 07:05PM	UMH Properties and 4 More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-26 08:00AM	MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-13-26 04:15PM	MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth (GlobeNewswire) -5.75%
Jun-12-26 08:52AM	MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX) (InvestorsHub)
07:00AM	MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism (GlobeNewswire)
Jun-11-26 05:27AM	J&J looks to widen Imaavys use; $300M backs rare disease drug launch (BioPharma Dive) +20.20%
Jun-01-26 08:00AM	MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 (GlobeNewswire)
May-26-26 08:00AM	MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City (GlobeNewswire)
May-11-26 07:00AM	MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing (GlobeNewswire)
May-07-26 08:00AM	MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +8.06%
07:00AM	Loading…
07:00AM	MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award (GlobeNewswire)
Apr-23-26 08:00AM	MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio (GlobeNewswire)
Apr-03-26 08:00AM	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-12-26 08:00AM	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-10-26 08:00AM	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer (GlobeNewswire)
Mar-09-26 10:21AM	CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism (GlobeNewswire) -8.54%
08:00AM	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism (GlobeNewswire)
Feb-28-26 07:05PM	MBX Biosciences Calls 2026 Pivotal With Phase 3 Plans, Obesity Program, and $460M Cash Runway (MarketBeat)
Feb-23-26 08:00AM	MBX Biosciences to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.63%
Feb-20-26 06:53PM	TripAdvisor, Orthofix Medical, and More Stocks See Action From Activist Investors (Barrons.com) -6.63%
Feb-11-26 08:00AM	MBX Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.11%
Jan-22-26 08:00AM	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair (GlobeNewswire)
Jan-11-26 04:00PM	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 11:11PM	MBX Biosciences (MBX) Faces Platform Validation Challenge as Near-Term Hypoglycemia Data Catalyst in Q2 2026 May Lack Differentiation (Insider Monkey)
08:00AM	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
09:55AM	Loading…
Dec-01-25 09:55AM	How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% (Zacks)
09:20AM	Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus (Zacks)
Nov-18-25 08:00AM	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-25 09:55AM	Wall Street Analysts See a 142% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Nov-06-25 08:00AM	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +9.71%
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
Oct-29-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 228.51%: Read This Before Placing a Bet (Zacks) +8.69%
Oct-20-25 08:00AM	MBX Biosciences to Participate in November Investor Conferences (GlobeNewswire) +7.64%
Oct-10-25 06:20PM	8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors (Barrons.com) -5.99%
Oct-09-25 09:55AM	Wall Street Analysts See a 280.14% Upside in MBX Biosciences, Inc. (MBX): Can the Stock Really Move This High? (Zacks)
Oct-08-25 07:00AM	Biotech and Medical Tech Stocks Report Breakthrough Clinical Trial Updates (Newsfile)
Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azoulay Salomon	Chief Medical Officer	Nov 04 '26	Sale	53.96	373	20,127	14,026	Nov 05 04:10 PM
Azoulay Salomon	Officer	Nov 04 '26	Proposed Sale	53.96	373	20,127		Nov 04 03:12 PM
Hawryluk P. Kent	Former Officer	Aug 17 '26	Proposed Sale	68.29	3,745	255,737		Aug 17 03:41 PM
Azoulay Salomon	Chief Medical Officer	Aug 04 '26	Sale	65.77	370	24,335	14,399	Aug 05 04:57 PM
Hawryluk P. Kent	Officer	Aug 04 '26	Proposed Sale	65.77	936	61,563		Aug 04 04:44 PM
Azoulay Salomon	Officer	Aug 04 '26	Proposed Sale	65.77	370	24,336		Aug 04 04:42 PM
Bartram Richard	Former Officer	Jun 10 '26	Proposed Sale	30.55	9,167	280,010		Jun 10 12:41 PM
Bartram Richard	Former Officer	Jun 09 '26	Proposed Sale	29.66	10,833	321,273		Jun 09 04:38 PM
Bartram Richard	Former Officer	May 13 '26	Proposed Sale	36.95	15,000	554,296		May 13 04:17 PM
Azoulay Salomon	Chief Medical Officer	May 08 '26	Option Exercise	11.65	70,003	815,348	69,769	May 11 04:01 PM
Azoulay Salomon	Chief Medical Officer	May 08 '26	Sale	38.36	70,003	2,685,515	14,769	May 11 04:01 PM
Bartram Richard	Former Officer	May 11 '26	Proposed Sale	44.08	22,500	991,901		May 11 03:54 PM
Azoulay Salomon	Officer	May 08 '26	Proposed Sale	38.37	70,003	2,685,679		May 08 04:10 PM
Azoulay Salomon	Chief Medical Officer	May 06 '26	Sale	29.54	231	6,824	14,769	May 08 04:02 PM
Hawryluk P. Kent	President & CEO	May 06 '26	Sale	29.54	607	17,931	727,667	May 08 04:00 PM
Bartram Richard	Former Officer	May 08 '26	Proposed Sale	37.96	10,000	379,562		May 08 12:21 PM
Bartram Richard	Former Officer	May 07 '26	Proposed Sale	32.20	10,000	322,050		May 07 12:47 PM
Hawryluk P. Kent	Officer	May 06 '26	Proposed Sale	29.54	607	17,934		May 06 03:29 PM
Azoulay Salomon	Officer	May 06 '26	Proposed Sale	29.54	231	6,825		May 06 03:12 PM
Bartram Richard	Former Officer	May 01 '26	Proposed Sale	31.80	5,000	159,000		May 01 02:59 PM
Bartram Richard	Former Officer	Apr 22 '26	Proposed Sale	32.75	10,423	341,378		Apr 22 11:59 AM
Bartram Richard	Former Officer	Mar 25 '26	Proposed Sale	28.48	1,061	30,217		Mar 25 03:20 PM
Bartram Richard	Former Officer	Mar 16 '26	Proposed Sale	30.05	10,000	300,471		Mar 16 02:47 PM
Hawryluk P. Kent	President & CEO	Mar 13 '26	Buy	28.41	18,500	525,663	486,777	Mar 16 08:02 AM
Hawryluk P. Kent	President & CEO	Feb 26 '26	Option Exercise	16.00	28,768	460,288	728,274	Feb 27 04:07 PM
CORNELIUS JAMES M	Former Director	Jan 12 '26	Proposed Sale	35.74	30,864	1,102,991		Jan 12 03:41 PM

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Executive ChairpersonMr. Steven L. Hoerter

Chief Medical OfficerDr. Salomon Azoulay M.D.

Chief Financial OfficerMr. John W. Smither CPA

Senior Vice President of Investor Relations & Corporate CommunicationsMr. Pete De Spain

Chief Legal OfficerMr. Jeffrey Held J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBX

MBX Biosciences Inc

Upgrade your Finviz experience